(3/4) But the market for antibiotics is broken and private investment is sorely lacking, making it exceedingly difficult to advance even the most-promising candidates through clinical development and to patients.
Comments
Log in with your Bluesky account to leave a comment
(4/4)It was illuminating to think through these challenges with Henry Skinner of the @amractionfund.bsky.social and Dr. Christina Yen in a new paper for @bulletinatomic.bsky.social. As we note, to fully reap the benefits of AI, antibiotic policies and market dynamics must evolve alongside AI.
Comments